×
About 4,218 results

ALLMedicine™ Astrocytoma Center

Research & Reviews  1,536 results

The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astr...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095826
Pathology Oncology Research : POR; Chang SJ, Chao CT et. al.

May 17th, 2022 - Background: CXCL13 may act as a mediator of tumor-associated macrophage immunity during malignant progression. Objective: The present study clarifies the clinicopathological significances of CXCL13 and its corresponding trend with M2 macrophage in...

BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
https://clinicaltrials.gov/ct2/show/NCT05375318

May 16th, 2022 - High-grade glioma (HGG) are the most aggressive malignant primary brain tumor in adults with a median survival rate of 12-15 months. It still carries a poor prognosis despite aggressive treatment, which includes tumor resection followed by chemo-r...

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
https://clinicaltrials.gov/ct2/show/NCT04782609

May 9th, 2022 - This is a 2-part multicenter Phase 1b study designed to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation des...

CXCL14 promotes a robust brain tumor-associated immune response in glioma.
https://doi.org/10.1158/1078-0432.CCR-21-2830
Clinical Cancer Research : an Official Journal of the Ame... Kumar A, Mohamed E et. al.

May 6th, 2022 - The immunosuppressive tumor microenvironment present in the majority of diffuse glioma limits therapeutic response to immunotherapy. As the determinants of the glioma-associated immune response are relatively poorly understood, the study of glioma...

Diencephalic syndrome in a female child due to intracranial germinoma: a case report.
https://doi.org/10.1007/s00381-022-05528-1 10.3345/kjp.2015.58.1.28 10.1016/s0022-3476(76)80260-0 10.1542/peds.2004-2237 10.1542/peds.2012-3196 10.3340/jkns.2018.0056 10.1007/s11060-021-03709-7 10.1007/s00432-018-2743-0 10.3171/2018.9.PEDS18181 10.1016/S1470-2045(05)70245-X 10.4103/0028-3886.314587
Child's Nervous System : ChNS : Official Journal of the I... Ju Y, Liu P et. al.

May 5th, 2022 - Diencephalic syndrome (DS) is a rare syndrome with failure to thrive (FTT) as the primary manifestation, which is often associated with astrocytoma or glioma and rarely caused by germinoma. To our knowledge, there are no reports of female patients...

see more →

Guidelines  3 results

Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
https://doi.org/10.1200/JCO.21.02036
Journal of Clinical Oncology : Official Journal of the Am... Mohile NA, Messersmith H et. al.

Dec 14th, 2021 - To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature. Fifty-nine rand...

The role of initial chemotherapy for the treatment of adults with diffuse low grade gli...
https://doi.org/10.1007/s11060-015-1931-x
Journal of Neuro-oncology; Ziu M, Kalkanis SN et. al.

Nov 5th, 2015 - Adult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma). Is there a role for chemotherapy as adjuvant therapy of choice in treatment...

The role of surgery in the management of patients with diffuse low grade glioma: A syst...
https://doi.org/10.1007/s11060-015-1867-1
Journal of Neuro-oncology; Aghi MK, Nahed BV et. al.

Nov 5th, 2015 - Should patients with imaging suggestive of low grade glioma (LGG) undergo observation versus treatment involving a surgical procedure? These recommendations apply to adults with imaging suggestive of a WHO grade 2 glioma (oligodendroglioma, astroc...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  47 results

BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
https://clinicaltrials.gov/ct2/show/NCT05375318

May 16th, 2022 - High-grade glioma (HGG) are the most aggressive malignant primary brain tumor in adults with a median survival rate of 12-15 months. It still carries a poor prognosis despite aggressive treatment, which includes tumor resection followed by chemo-r...

Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
https://clinicaltrials.gov/ct2/show/NCT04782609

May 9th, 2022 - This is a 2-part multicenter Phase 1b study designed to test the safety, tolerability and pharmacokinetics of single agent oral icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation des...

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
https://clinicaltrials.gov/ct2/show/NCT04430842

Apr 19th, 2022 - This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expre...

3D Prediction of Patient-Specific Response
https://clinicaltrials.gov/ct2/show/NCT03561207

Apr 8th, 2022 - This protocol defines a prospective, open-label, multi-institutional, non-interventional study for the purpose of examining the Assay's clinical use and potential to impact patient outcomes. This Study will establish a registry of clinical paramet...

Trial in Low Grade Glioma Patients: Wait or Treat
https://clinicaltrials.gov/ct2/show/NCT03763422

Feb 1st, 2022 - The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment. It will establish whether ...

see more →

News  68 results

Targeted Combo Notches Rare Success in Glioblastoma
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma

Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...

Net Guides: Childhood Tumors
https://www.onclive.com/view/net-guides-childhood-tumors

Mar 15th, 2022 - //THE ONLINE ONCOLOGIST™ American Society of Pediatric Hematology/Oncology The American Society of Pediatric Hematology/Oncology (ASPHO) is a multidisciplinary organization that works to promote the care of children and adolescents with blo...

Brain Tumors Exact Higher Mortality Toll in Men Than Women
https://www.medscape.com/viewarticle/968594

Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...

Exceptional Responder Provides Treatment Clues in Bladder Cancer
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors

Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...

see more →

Patient Education  2 results see all →